Review



anti c23  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    Cell Signaling Technology Inc anti c23
    A–C HeLa I- Ppo I cells were pre-treated with ATM inhibitor (ATMi; KU-55933) or EHMT2 inhibitor (EHMT2i; UNC0638) for 1 h prior to I- Ppo I induction for 4 h. After fixation, cells were subjected to immunofluorescence <t>with</t> <t>anti-C23</t> ( A ), anti-Ki-67 ( B ), anti-UBF ( C ) or anti-γH2AX antibodies, respectively. The dashed circles outline margins of the nuclei. Percentages of cells with the indicated protein-containing nucleolar caps were quantified from three experiments. D – F EHMT2-KO HeLa I- Ppo I cells were processed for immunofluorescence as described in ( A – C ). Cells were labeled with anti-C23 ( D ), anti-Ki-67 ( E ), anti-UBF ( F ) or anti-γH2AX antibodies, respectively. Nuclei were counterstained with DAPI. Percentages of cells with the nucleolar caps were quantified from three experiments. Bars represent mean ± SEM; ns not significant; * P < 0.05; ** P < 0.01; *** P < 0.001.
    Anti C23, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 128 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+nucleolin/Nucleolin+Rabbit+mAb/pmc13039405-318-18-20
    Average 95 stars, based on 128 article reviews
    anti c23 - by Bioz Stars, 2026-09
    95/100 stars

    Images

    1) Product Images from "The EHMT2-MBLAC2 axis suppresses ribosomal DNA transcription in response to nucleolar DNA damage"

    Article Title: The EHMT2-MBLAC2 axis suppresses ribosomal DNA transcription in response to nucleolar DNA damage

    Journal: Cell Death & Disease

    doi: 10.1038/s41419-026-08616-1

    A–C HeLa I- Ppo I cells were pre-treated with ATM inhibitor (ATMi; KU-55933) or EHMT2 inhibitor (EHMT2i; UNC0638) for 1 h prior to I- Ppo I induction for 4 h. After fixation, cells were subjected to immunofluorescence with anti-C23 ( A ), anti-Ki-67 ( B ), anti-UBF ( C ) or anti-γH2AX antibodies, respectively. The dashed circles outline margins of the nuclei. Percentages of cells with the indicated protein-containing nucleolar caps were quantified from three experiments. D – F EHMT2-KO HeLa I- Ppo I cells were processed for immunofluorescence as described in ( A – C ). Cells were labeled with anti-C23 ( D ), anti-Ki-67 ( E ), anti-UBF ( F ) or anti-γH2AX antibodies, respectively. Nuclei were counterstained with DAPI. Percentages of cells with the nucleolar caps were quantified from three experiments. Bars represent mean ± SEM; ns not significant; * P < 0.05; ** P < 0.01; *** P < 0.001.
    Figure Legend Snippet: A–C HeLa I- Ppo I cells were pre-treated with ATM inhibitor (ATMi; KU-55933) or EHMT2 inhibitor (EHMT2i; UNC0638) for 1 h prior to I- Ppo I induction for 4 h. After fixation, cells were subjected to immunofluorescence with anti-C23 ( A ), anti-Ki-67 ( B ), anti-UBF ( C ) or anti-γH2AX antibodies, respectively. The dashed circles outline margins of the nuclei. Percentages of cells with the indicated protein-containing nucleolar caps were quantified from three experiments. D – F EHMT2-KO HeLa I- Ppo I cells were processed for immunofluorescence as described in ( A – C ). Cells were labeled with anti-C23 ( D ), anti-Ki-67 ( E ), anti-UBF ( F ) or anti-γH2AX antibodies, respectively. Nuclei were counterstained with DAPI. Percentages of cells with the nucleolar caps were quantified from three experiments. Bars represent mean ± SEM; ns not significant; * P < 0.05; ** P < 0.01; *** P < 0.001.

    Techniques Used: Immunofluorescence, Labeling

    A The cellular localization of MBLAC2 in HeLa I- Ppo I cells following rDNA DSBs induction. HeLa I- Ppo I cells were transfected with EGFP-MBLAC2 and were treated with Shield-1 and 4-OHT for 4 h. Fixed cells were labeled with anti-53BP1, anti-γH2AX or anti-C23 antibodies. Nuclei were counterstained with DAPI. Enlarged images show the details of the indicated proteins. Quantification of relative signal intensities of EGFP-EHMT2, 53BP1, γH2AX and C23 was performed by ImageJ. The white lines in the enlargements of the representative images indicate the lines for analysis. The edge of the indicated nucleolar caps was labeled with dotted circle. B Analysis of nucleolar transcription activity by EU incorporation assay in MBLAC2-inactivated HeLa I- Ppo I cells following rDNA DSBs induction. Cells transduced with control (shCTR) or two independent MBLAC2-targeted shRNAs were induced for rDNA DSBs for 4 h. EU nucleolar intensity was subsequently determined by EU incorporation assay. At least 200 cells exhibiting well-circumscribed nucleoli were quantitatively assessed across two independent experiments. Quantification of relative EU nucleolar intensity is shown in Tukey boxplots. C Nucleolar EU intensities were analyzed in HeLa I- Ppo I cells treated with the EHMT2 gRNA or MBLAC2 siRNA after I- Ppo I induction. Relative nucleolar EU intensity was quantified from at least two independent experiments. Immunoblot of MBLAC2 and EHMT2 in the HeLa I- Ppo I cells induced with the indicated gRNA or siRNA. D Colony survival of HeLa I- Ppo I cells transfected with CTR siRNA and siRNA targeting MBLAC2 or EHMT2 following I- Ppo I induction, respectively. Cells were induced for rDNA DSBs for 5 min. After washing with PBS twice, cells were allowed to grow for two weeks before harvest and Coomassie blue staining. The relative outgrowth of the colonies between groups were quantified and plotted. The protein expression of MBLAC2 and EHMT2 in HeLa I- Ppo I cells transfected with the indicated siRNAs were examined by immunoblot. E Immunoblot of MBLAC2 and EHMT2 in the HeLa I- Ppo I cells transduced with control gRNA (CTR gRNA) and two EHMT2 gRNAs (EHMT2 KO1 and EHMT2 KO2). F shRNA-mediated MBLAC2 knockdown efficiency was measured by Western blotting. G The EHMT2-MBLAC2 interaction was confirmed by Co-immunoprecipitation (Co-IP). Flag-DYRK1B was used as the positive control. H HeLa I- Ppo I cells transduced with control gRNA (CTR gRNA) and two EHMT2 gRNAs (EHMT2 KO1 and EHMT2 KO2) were treated with cycloheximide for 0, 5, and 10 h. The protein expression of MBLAC2 and EHMT2 in HeLa I- Ppo I cells was examined by immunoblot. I The relative MBLAC2 protein level in HeLa I-PpoI cells treated with cycloheximide as depicted in ( A ) was measured. Data were derived from three independent experiments. J HeLa I-PpoI cells were transduced with control gRNA (CTR gRNA) and two EHMT2 gRNAs (EHMT2 KO1 and EHMT2 KO2). Fold change of MBLAC2 mRNA in I- Ppo I cells treated with cycloheximide was determined by RT-qPCR. Quantification of MBLAC2 mRNA fold change was from three independent experiments. K Proposed working model of EHMT2-MBLAC2 axis in promoting rDNA DSB-induced transcriptional suppression. Bars represent mean ± SEM; ns not significant; * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.
    Figure Legend Snippet: A The cellular localization of MBLAC2 in HeLa I- Ppo I cells following rDNA DSBs induction. HeLa I- Ppo I cells were transfected with EGFP-MBLAC2 and were treated with Shield-1 and 4-OHT for 4 h. Fixed cells were labeled with anti-53BP1, anti-γH2AX or anti-C23 antibodies. Nuclei were counterstained with DAPI. Enlarged images show the details of the indicated proteins. Quantification of relative signal intensities of EGFP-EHMT2, 53BP1, γH2AX and C23 was performed by ImageJ. The white lines in the enlargements of the representative images indicate the lines for analysis. The edge of the indicated nucleolar caps was labeled with dotted circle. B Analysis of nucleolar transcription activity by EU incorporation assay in MBLAC2-inactivated HeLa I- Ppo I cells following rDNA DSBs induction. Cells transduced with control (shCTR) or two independent MBLAC2-targeted shRNAs were induced for rDNA DSBs for 4 h. EU nucleolar intensity was subsequently determined by EU incorporation assay. At least 200 cells exhibiting well-circumscribed nucleoli were quantitatively assessed across two independent experiments. Quantification of relative EU nucleolar intensity is shown in Tukey boxplots. C Nucleolar EU intensities were analyzed in HeLa I- Ppo I cells treated with the EHMT2 gRNA or MBLAC2 siRNA after I- Ppo I induction. Relative nucleolar EU intensity was quantified from at least two independent experiments. Immunoblot of MBLAC2 and EHMT2 in the HeLa I- Ppo I cells induced with the indicated gRNA or siRNA. D Colony survival of HeLa I- Ppo I cells transfected with CTR siRNA and siRNA targeting MBLAC2 or EHMT2 following I- Ppo I induction, respectively. Cells were induced for rDNA DSBs for 5 min. After washing with PBS twice, cells were allowed to grow for two weeks before harvest and Coomassie blue staining. The relative outgrowth of the colonies between groups were quantified and plotted. The protein expression of MBLAC2 and EHMT2 in HeLa I- Ppo I cells transfected with the indicated siRNAs were examined by immunoblot. E Immunoblot of MBLAC2 and EHMT2 in the HeLa I- Ppo I cells transduced with control gRNA (CTR gRNA) and two EHMT2 gRNAs (EHMT2 KO1 and EHMT2 KO2). F shRNA-mediated MBLAC2 knockdown efficiency was measured by Western blotting. G The EHMT2-MBLAC2 interaction was confirmed by Co-immunoprecipitation (Co-IP). Flag-DYRK1B was used as the positive control. H HeLa I- Ppo I cells transduced with control gRNA (CTR gRNA) and two EHMT2 gRNAs (EHMT2 KO1 and EHMT2 KO2) were treated with cycloheximide for 0, 5, and 10 h. The protein expression of MBLAC2 and EHMT2 in HeLa I- Ppo I cells was examined by immunoblot. I The relative MBLAC2 protein level in HeLa I-PpoI cells treated with cycloheximide as depicted in ( A ) was measured. Data were derived from three independent experiments. J HeLa I-PpoI cells were transduced with control gRNA (CTR gRNA) and two EHMT2 gRNAs (EHMT2 KO1 and EHMT2 KO2). Fold change of MBLAC2 mRNA in I- Ppo I cells treated with cycloheximide was determined by RT-qPCR. Quantification of MBLAC2 mRNA fold change was from three independent experiments. K Proposed working model of EHMT2-MBLAC2 axis in promoting rDNA DSB-induced transcriptional suppression. Bars represent mean ± SEM; ns not significant; * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.

    Techniques Used: Transfection, Labeling, Activity Assay, Transduction, Control, Western Blot, Staining, Expressing, shRNA, Knockdown, Immunoprecipitation, Co-Immunoprecipitation Assay, Positive Control, Derivative Assay, Quantitative RT-PCR

    Related Articles

    other:

    Article Title: Disruption of nuclear speckle integrity dysregulates RNA splicing in C9ORF72-FTD/ALS.
    Article Snippet: In brief Dysregulation of RNA processing contributes to multiple neurodegenerative diseases.. In this article, Wu et al. demonstrated that nuclear speckle dysfunction represents a converging toxic pathway contributed by both (GGGGCC)n repeat RNA and the noncanonical translation product polyGR in C9ORF72-FTD/ALS.. Impaired nuclear speckle integrity induces RNA mis-splicing and causes neuronal degeneration.

    Article Title: Re-organization of nucleolar architecture in myogenic differentiation.
    Article Snippet: Anti-nucleolin (D4C7O: #14574 or E5M7K: #87792) antibody was obtained from Cell Signaling technology.

    Article Title: TEAD1 condensates are transcriptionally inactive storage sites on the pericentromeric heterochromatin
    Article Snippet: The following primary and secondary antibodies were used: anti-YAP (1:150; Cell Signaling, 14074S); anti-TEAD1 (BD Biosciences; 610923); anti-BRD4 (Abcam; 207057); anti-TEAD2 (Abcam; 54374), anti-TEAD3 (Abnova; H00007005-MO1), anti-TEAD4 (Abcam; 58310), anti-H3K27ac (Active Motif; 39685), anti-H3K9me3 (Active Motif; 39161), anti-RNAPIIS2P (Abcam; 193468), anti-coilin (Abcam; 87913), anti-PML (Abcam; 96051), anti-sc35 (Abcam; 11826), AmyTracker680 (Ebba Biotech), anti-nucleolin (14574, Cell Signaling), Goat anti-Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 568 (1:1000; Thermo fisher, A11011).

    Article Title: Ginsenoside Rc inhibits TGF-β signaling and downregulates nucleolin to mitigate oxidative stress-induced muscle atrophy.
    Article Snippet: This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record.. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article.. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

    Binding Assay:

    Article Title: RAD51C-XRCC3 complex regulates FANCM-mediated R-loop resolution to safeguard genome integrity
    Article Snippet: .. Antibodies used in this study are as follows: anti-S9.6 (Sigma-Aldrich; catalog no. MABE1095; RRID: AB_2861387), anti-ssDNA (Sigma-Aldrich; catalog no. MAB3034), anti-FLAG (Cell Signaling Technology (CST); catalog no. 14793; RRID: AB_2572291), anti-FLAG (Sigma-Aldrich; catalog no. F7425; RRID: AB_439687), anti-H2AX (pS139) (BD Biosciences; catalog no. 560443; RRID: AB_1645592), anti-RAD51 [Santa Cruz (SC); catalog no. sc-8349; RRID: AB_2253533], anti-RAD51C (SC; catalog no. sc-56214; RRID: AB_2238197), anti-RAD51C (Abcam; catalog no. ab-72063; RRID: AB_2177279), anti-RAD51B (SC; catalog no. sc-377192), anti-RAD51D (SC; catalog no. sc-53432), anti-XRCC2 (SC; catalog no. sc-365854), anti-XRCC2 (Abcam; catalog no. AB180752 ), anti-XRCC3 (SC; catalog no. sc-271714), anti-XRCC3 (Abcam; catalog no. AB58467; RRID: AB_883592), anti-MCM3 (SC; catalog no. sc-365616; RRID: AB_10846721), anti-α-tubulin (SC; catalog no. sc-5286; RRID: AB_628411), anti-FANCD2 (Abcam; catalog no. AB108928 ; RRID: AB_10862535), anti-FANCM (Thermo Fisher Scientific; catalog no. PA5-76229; RRID: AB_2719956), anti-FANCM (Novus; catalog no. NBP2-50418; RRID: AB_2716711), anti-nucleolin (Cell Signaling Technology; catalog no. 14574; RRID: AB_2798519), anti-HA (Roche; catalog no. 10952100), mouse anti-rabbit immunoglobulin G (IgG)–horseradish peroxidase (HRP) (SC; catalog no. sc-2357; RRID: AB_628497), m-IgG binding protein–HRP (SC; catalog no. sc-516102; RRID: AB_2687626), anti-mouse tetramethyl rhodamine isothiocyanate (TRITC) (Sigma-Aldrich; catalog no. T5393; RRID: AB_261699), anti-rabbit fluorescein isothiocyanate (FITC) (Sigma-Aldrich; catalog no. F0382; RRID: AB_259384), anti-mouse IgG H&L (Alexa Fluor 488) (Abcam; catalog no. ab150125), donkey anti-rat Alexa Fluor 594 (Abcam; catalog no. ab150156; RRID: AB_2890252), rat anti-BrdU (Abcam; catalog no. ab6326; RRID: AB_305426), mouse anti-BrdU (BD Biosciences; catalog no. 347580; RRID: AB_400326), anti-PCNA (Cell Signaling Technology; catalog no. 2586; RRID: AB_2160343), and anti-RNAPIIS2P (Abcam; catalog no. ab5095; RRID: AB_304749). .. Other commercial reagents used in this study are as follows: HU (Sigma-Aldrich; catalog no. H8627), Aph (Sigma-Aldrich; catalog no. A0781), CPT (Sigma-Aldrich; catalog no. C9911), 4′,6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich; catalog no. D8417), 5-chloro-2-deoxyuridine (Sigma-Aldrich; catalog no. C6891), 5-iodo-2-deoxyuridine (Sigma-Aldrich; catalog no. I7125), protease inhibitor cocktail (Roche; catalog no.11836153001), thiazolyl blue tetrazolium bromide (Sigma-Aldrich; catalog no. M2128), agarose low gelling temperature (Sigma-Aldrich; catalog no. A9414), Protein G Sepharose beads (Cytiva; catalog no. GE17-0618-01), Protein A Sepharose beads (Cytiva; catalog no. GE17-0780-01), 5-ethynyl-2-deoxyuridine (Thermo Fisher Scientific; catalog no. A10044), benzonase (Sigma-Aldrich; catalog no. E1014), l -ascorbic acid (Sigma-Aldrich; catalog no. A92902), Mowiol 4-88 (Merck; catalog no. 81381), Immobilon Western Chemiluminescent HRP Substrate (Millipore; catalog no. WBKLS0500), Duolink In Situ PLA Probe Anti-Rabbit PLUS (Merck; catalog no. DUO92002), Duolink In Situ PLA Probe Anti-Mouse MINUS (Merck; catalog no. DUO92004), Duolink In Situ Detection Reagents Red (Merck; catalog no. DUO92008), and Click-iT EdU Alexa Fluor 647 Imaging Kit (Thermo Fisher Scientific; catalog no. C10340 ).

    Immunocytochemistry:

    Article Title: Treacle’s ability to form liquid-like phase condensates is essential for nucleolar fibrillar center assembly, efficient rRNA transcription and processing, and rRNA gene repair
    Article Snippet: Antibody , Anti-Fibrillarin (Rabbit monoclonal) , Abcam , ab166630, RRID: AB_2928100 , ICC (1:500). .. Antibody , Anti-Nucleolin (Rabbit monoclonal) , Cell Signaling , 14574, RRID: AB_2798519 , ICC (1:500). .. Antibody , Anti-B23 (Mouse monoclonal) , Sigma-Aldrich , B0556, RRID: AB_2154872 , ICC (1:300).

    Western Blot:

    Article Title: CDC40 suppression induces CDCA5 splicing defects and anti-proliferative effects in lung cancer cells.
    Article Snippet: .. Primary antibodies used for western blot analysis were: anti-CDC40 (Abcam, ab175924, 1:1,000), anti-H3 (Cell Signaling Technology, 14269S,1:1,000), anti-GAPDH (Cell Signaling Technology, 2118S, 1:1,000), anti-CDC5 (Abcam, ab51320, 1:1,000), anti-DYKDDDDK (Sigma, F1804, 1:2,000), anti-PRP19 (Abcam, ab126776, 1:1000), anti-CWC15 (Abcam, ab188345, 1:1000), anti-PPIL1 (Abcam, ab154188, 1:1000), anti-PLRG1 (Abcam, ab86050, 1:1000), anti-EGFR (Abcam, ab52894, 1:5,000), anti-p21 (Cell Signaling Technology, 2947S, 1:5,000), Translation Initiation Complex Antibody Sampler Kit (Cell Scientific Reports | (2025) 15:315 11| https://doi.org/10.1038/s41598-024-83337-z signalling Technology, 4763 T, 1:5000), anti-eIF2α (Cell Signaling Technology, 5324S, 1:5000), anti-PhosphoeIF2α (Ser51) (Cell Signaling Technology, 9721S, 1:5000), anti-Nucleolin (Cell Signaling Technology, 14574S, 1:1000). .. Secondary antibodies used were anti-Rabbit (Bio-Rad, 1,706,515, 1:10,000) and anti-Mouse (Bio-Rad, 1,721,011, 1:10,000).



    Similar Products

    96
    Proteintech anti nucleolin
    Anti Nucleolin, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+nucleolin/Histone-H3+Antibody/pm41916977-347-14-15
    Average 96 stars, based on 1 article reviews
    anti nucleolin - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    95
    Santa Cruz Biotechnology mouse monoclonal anti nucleolin
    Mouse Monoclonal Anti Nucleolin, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+nucleolin/C23+Antibody/pmc12799909-4-0-7
    Average 95 stars, based on 1 article reviews
    mouse monoclonal anti nucleolin - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    93
    novus biologicals NB600-241
    Nb600 241, supplied by novus biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+nucleolin/Nucleolin+Antibody/pmc13025875-10-0-2
    Average 93 stars, based on 1 article reviews
    NB600-241 - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    95
    Cell Signaling Technology Inc anti c23
    A–C HeLa I- Ppo I cells were pre-treated with ATM inhibitor (ATMi; KU-55933) or EHMT2 inhibitor (EHMT2i; UNC0638) for 1 h prior to I- Ppo I induction for 4 h. After fixation, cells were subjected to immunofluorescence <t>with</t> <t>anti-C23</t> ( A ), anti-Ki-67 ( B ), anti-UBF ( C ) or anti-γH2AX antibodies, respectively. The dashed circles outline margins of the nuclei. Percentages of cells with the indicated protein-containing nucleolar caps were quantified from three experiments. D – F EHMT2-KO HeLa I- Ppo I cells were processed for immunofluorescence as described in ( A – C ). Cells were labeled with anti-C23 ( D ), anti-Ki-67 ( E ), anti-UBF ( F ) or anti-γH2AX antibodies, respectively. Nuclei were counterstained with DAPI. Percentages of cells with the nucleolar caps were quantified from three experiments. Bars represent mean ± SEM; ns not significant; * P < 0.05; ** P < 0.01; *** P < 0.001.
    Anti C23, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+nucleolin/Nucleolin+Rabbit+mAb/pmc13039405-318-18-20
    Average 95 stars, based on 1 article reviews
    anti c23 - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    95
    Santa Cruz Biotechnology antibody nucleolin c23
    A–C HeLa I- Ppo I cells were pre-treated with ATM inhibitor (ATMi; KU-55933) or EHMT2 inhibitor (EHMT2i; UNC0638) for 1 h prior to I- Ppo I induction for 4 h. After fixation, cells were subjected to immunofluorescence <t>with</t> <t>anti-C23</t> ( A ), anti-Ki-67 ( B ), anti-UBF ( C ) or anti-γH2AX antibodies, respectively. The dashed circles outline margins of the nuclei. Percentages of cells with the indicated protein-containing nucleolar caps were quantified from three experiments. D – F EHMT2-KO HeLa I- Ppo I cells were processed for immunofluorescence as described in ( A – C ). Cells were labeled with anti-C23 ( D ), anti-Ki-67 ( E ), anti-UBF ( F ) or anti-γH2AX antibodies, respectively. Nuclei were counterstained with DAPI. Percentages of cells with the nucleolar caps were quantified from three experiments. Bars represent mean ± SEM; ns not significant; * P < 0.05; ** P < 0.01; *** P < 0.001.
    Antibody Nucleolin C23, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+nucleolin/C23+Antibody/bio_rxiv__64898__2026__03__11__711022-136-30-35
    Average 95 stars, based on 1 article reviews
    antibody nucleolin c23 - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    95
    Cell Signaling Technology Inc rabbit anti nucleolin
    A–C HeLa I- Ppo I cells were pre-treated with ATM inhibitor (ATMi; KU-55933) or EHMT2 inhibitor (EHMT2i; UNC0638) for 1 h prior to I- Ppo I induction for 4 h. After fixation, cells were subjected to immunofluorescence <t>with</t> <t>anti-C23</t> ( A ), anti-Ki-67 ( B ), anti-UBF ( C ) or anti-γH2AX antibodies, respectively. The dashed circles outline margins of the nuclei. Percentages of cells with the indicated protein-containing nucleolar caps were quantified from three experiments. D – F EHMT2-KO HeLa I- Ppo I cells were processed for immunofluorescence as described in ( A – C ). Cells were labeled with anti-C23 ( D ), anti-Ki-67 ( E ), anti-UBF ( F ) or anti-γH2AX antibodies, respectively. Nuclei were counterstained with DAPI. Percentages of cells with the nucleolar caps were quantified from three experiments. Bars represent mean ± SEM; ns not significant; * P < 0.05; ** P < 0.01; *** P < 0.001.
    Rabbit Anti Nucleolin, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+nucleolin/Nucleolin+Rabbit+mAb/med_rxiv__64898__2026__02__26__26347174-59-13-16
    Average 95 stars, based on 1 article reviews
    rabbit anti nucleolin - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    95
    Cell Signaling Technology Inc anti rabbit nucleolin
    Ai , Left, representative immunocytochemistry micrographs of detyrMT (green), actin (red) and nuclei (HOECHST, blue). White arrow indicates detyrMT inside the NI. Right, scatter plot of NI quantification in control, PTL and CytD-treated cardiomyocytes (N=3-5 rats, 44-106 nuclei). Aii , Line-scan schematic of cytoplasmic and nucleoplasmic CaTs in a cardiomyocyte. Aiii , Representative recordings of distinct subcellular regions, as indicated in (ii), baseline quantification in control, PTL and CytD at 1 and 2.5Hz (bottom) (N=3-4 rats, 32-36 cells). Bi , Left, representative immunocytochemistry micrographs of <t>nucleolin</t> (yellow) and nuclei (HOECHST, blue). White arrow indicates NI-nucleoli localization. Right, scatter plots of area, circularity (N=5 rats,162-209 nucleoli) and NI number (N=3 rats, 60-57 nuclei) in control and BMH21-treated cells. Ci , Left, representative immunohistochemistry micrographs α-actinin (red) and nuclei (HOECHST, blue). Right, scatter plot of NI quantification in donor and DCM tissue (N=8 patients, 99-120 cells). Di , Animal model schematic. Representative immunocytochemistry micrographs of nuclei (HOECHST, grey) in Dii and detyrMT (grey) in Diii . Scatter plots of NI quantification ( Dii ) in control, 8-weeks and 16-weeks MI cardiomyocytes (N=3-4 rats, 40-44 cells) and detyrMT area quantification in control and 8-weeks MI cardiomyocytes (N=3 rats, 35-42 cells). Div , Left, mechano-Scanning Ion Conductance Microscopy representative topography and Young’s modulus maps. Right, Young’s modulus quantification in control and 8-weeks MI (N=3 rats, 33-36 cells). Representative immunocytochemistry micrographs of nucleolin (magenta) and nuclei (HOECHST, blue) in Ei and nucleophosmin (magenta), γH2AX-DNA damage (green) and nuclei (HOECHST, blue) in Eii . Scatter plots of circularity (N=3-4 rats, 96-137 nucleoli) and chromocenter Manders Coefficient (M1,M2) (N=3 rats, 43-49 cells) in control and MI cardiomyocytes ( Ei ) and γH2AX foci area ( Eii ) (N=3 rats, 48-63 cells). Eiii , Left, representative heatmap. Right, Brillouin shift absolute difference in control and 8-weeks cardiomyocytes (N=3 rats, 36-37 cells). Statistics: nested t-test ( Bi , Diii-iv ), unpaired t-test Kolmogorov-Smirnov ( Bi , Ci , Ei-iii ), non-parametric Kruskal Wallis with Dunn’s multiple comparison ( Ai , Dii , Ei ).Normality tested with Shapiro-Wilk.Data represent mean±SEM. Scale bar 5µm.
    Anti Rabbit Nucleolin, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+nucleolin/Nucleolin+Rabbit+mAb/bio_rxiv__64898__2026__02__24__707499-72-12-14
    Average 95 stars, based on 1 article reviews
    anti rabbit nucleolin - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    95
    Cell Signaling Technology Inc anti nucleolin
    Ai , Left, representative immunocytochemistry micrographs of detyrMT (green), actin (red) and nuclei (HOECHST, blue). White arrow indicates detyrMT inside the NI. Right, scatter plot of NI quantification in control, PTL and CytD-treated cardiomyocytes (N=3-5 rats, 44-106 nuclei). Aii , Line-scan schematic of cytoplasmic and nucleoplasmic CaTs in a cardiomyocyte. Aiii , Representative recordings of distinct subcellular regions, as indicated in (ii), baseline quantification in control, PTL and CytD at 1 and 2.5Hz (bottom) (N=3-4 rats, 32-36 cells). Bi , Left, representative immunocytochemistry micrographs of <t>nucleolin</t> (yellow) and nuclei (HOECHST, blue). White arrow indicates NI-nucleoli localization. Right, scatter plots of area, circularity (N=5 rats,162-209 nucleoli) and NI number (N=3 rats, 60-57 nuclei) in control and BMH21-treated cells. Ci , Left, representative immunohistochemistry micrographs α-actinin (red) and nuclei (HOECHST, blue). Right, scatter plot of NI quantification in donor and DCM tissue (N=8 patients, 99-120 cells). Di , Animal model schematic. Representative immunocytochemistry micrographs of nuclei (HOECHST, grey) in Dii and detyrMT (grey) in Diii . Scatter plots of NI quantification ( Dii ) in control, 8-weeks and 16-weeks MI cardiomyocytes (N=3-4 rats, 40-44 cells) and detyrMT area quantification in control and 8-weeks MI cardiomyocytes (N=3 rats, 35-42 cells). Div , Left, mechano-Scanning Ion Conductance Microscopy representative topography and Young’s modulus maps. Right, Young’s modulus quantification in control and 8-weeks MI (N=3 rats, 33-36 cells). Representative immunocytochemistry micrographs of nucleolin (magenta) and nuclei (HOECHST, blue) in Ei and nucleophosmin (magenta), γH2AX-DNA damage (green) and nuclei (HOECHST, blue) in Eii . Scatter plots of circularity (N=3-4 rats, 96-137 nucleoli) and chromocenter Manders Coefficient (M1,M2) (N=3 rats, 43-49 cells) in control and MI cardiomyocytes ( Ei ) and γH2AX foci area ( Eii ) (N=3 rats, 48-63 cells). Eiii , Left, representative heatmap. Right, Brillouin shift absolute difference in control and 8-weeks cardiomyocytes (N=3 rats, 36-37 cells). Statistics: nested t-test ( Bi , Diii-iv ), unpaired t-test Kolmogorov-Smirnov ( Bi , Ci , Ei-iii ), non-parametric Kruskal Wallis with Dunn’s multiple comparison ( Ai , Dii , Ei ).Normality tested with Shapiro-Wilk.Data represent mean±SEM. Scale bar 5µm.
    Anti Nucleolin, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+nucleolin/Nucleolin+Rabbit+mAb/pmc12922753-256-140-141
    Average 95 stars, based on 1 article reviews
    anti nucleolin - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    93
    Cell Signaling Technology Inc anti nucleolin antibody
    Ai , Left, representative immunocytochemistry micrographs of detyrMT (green), actin (red) and nuclei (HOECHST, blue). White arrow indicates detyrMT inside the NI. Right, scatter plot of NI quantification in control, PTL and CytD-treated cardiomyocytes (N=3-5 rats, 44-106 nuclei). Aii , Line-scan schematic of cytoplasmic and nucleoplasmic CaTs in a cardiomyocyte. Aiii , Representative recordings of distinct subcellular regions, as indicated in (ii), baseline quantification in control, PTL and CytD at 1 and 2.5Hz (bottom) (N=3-4 rats, 32-36 cells). Bi , Left, representative immunocytochemistry micrographs of <t>nucleolin</t> (yellow) and nuclei (HOECHST, blue). White arrow indicates NI-nucleoli localization. Right, scatter plots of area, circularity (N=5 rats,162-209 nucleoli) and NI number (N=3 rats, 60-57 nuclei) in control and BMH21-treated cells. Ci , Left, representative immunohistochemistry micrographs α-actinin (red) and nuclei (HOECHST, blue). Right, scatter plot of NI quantification in donor and DCM tissue (N=8 patients, 99-120 cells). Di , Animal model schematic. Representative immunocytochemistry micrographs of nuclei (HOECHST, grey) in Dii and detyrMT (grey) in Diii . Scatter plots of NI quantification ( Dii ) in control, 8-weeks and 16-weeks MI cardiomyocytes (N=3-4 rats, 40-44 cells) and detyrMT area quantification in control and 8-weeks MI cardiomyocytes (N=3 rats, 35-42 cells). Div , Left, mechano-Scanning Ion Conductance Microscopy representative topography and Young’s modulus maps. Right, Young’s modulus quantification in control and 8-weeks MI (N=3 rats, 33-36 cells). Representative immunocytochemistry micrographs of nucleolin (magenta) and nuclei (HOECHST, blue) in Ei and nucleophosmin (magenta), γH2AX-DNA damage (green) and nuclei (HOECHST, blue) in Eii . Scatter plots of circularity (N=3-4 rats, 96-137 nucleoli) and chromocenter Manders Coefficient (M1,M2) (N=3 rats, 43-49 cells) in control and MI cardiomyocytes ( Ei ) and γH2AX foci area ( Eii ) (N=3 rats, 48-63 cells). Eiii , Left, representative heatmap. Right, Brillouin shift absolute difference in control and 8-weeks cardiomyocytes (N=3 rats, 36-37 cells). Statistics: nested t-test ( Bi , Diii-iv ), unpaired t-test Kolmogorov-Smirnov ( Bi , Ci , Ei-iii ), non-parametric Kruskal Wallis with Dunn’s multiple comparison ( Ai , Dii , Ei ).Normality tested with Shapiro-Wilk.Data represent mean±SEM. Scale bar 5µm.
    Anti Nucleolin Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+nucleolin/CDT1+Antibody/bio_rxiv__64898__2026__02__13__705825-165-26-28
    Average 93 stars, based on 1 article reviews
    anti nucleolin antibody - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    Image Search Results


    A–C HeLa I- Ppo I cells were pre-treated with ATM inhibitor (ATMi; KU-55933) or EHMT2 inhibitor (EHMT2i; UNC0638) for 1 h prior to I- Ppo I induction for 4 h. After fixation, cells were subjected to immunofluorescence with anti-C23 ( A ), anti-Ki-67 ( B ), anti-UBF ( C ) or anti-γH2AX antibodies, respectively. The dashed circles outline margins of the nuclei. Percentages of cells with the indicated protein-containing nucleolar caps were quantified from three experiments. D – F EHMT2-KO HeLa I- Ppo I cells were processed for immunofluorescence as described in ( A – C ). Cells were labeled with anti-C23 ( D ), anti-Ki-67 ( E ), anti-UBF ( F ) or anti-γH2AX antibodies, respectively. Nuclei were counterstained with DAPI. Percentages of cells with the nucleolar caps were quantified from three experiments. Bars represent mean ± SEM; ns not significant; * P < 0.05; ** P < 0.01; *** P < 0.001.

    Journal: Cell Death & Disease

    Article Title: The EHMT2-MBLAC2 axis suppresses ribosomal DNA transcription in response to nucleolar DNA damage

    doi: 10.1038/s41419-026-08616-1

    Figure Lengend Snippet: A–C HeLa I- Ppo I cells were pre-treated with ATM inhibitor (ATMi; KU-55933) or EHMT2 inhibitor (EHMT2i; UNC0638) for 1 h prior to I- Ppo I induction for 4 h. After fixation, cells were subjected to immunofluorescence with anti-C23 ( A ), anti-Ki-67 ( B ), anti-UBF ( C ) or anti-γH2AX antibodies, respectively. The dashed circles outline margins of the nuclei. Percentages of cells with the indicated protein-containing nucleolar caps were quantified from three experiments. D – F EHMT2-KO HeLa I- Ppo I cells were processed for immunofluorescence as described in ( A – C ). Cells were labeled with anti-C23 ( D ), anti-Ki-67 ( E ), anti-UBF ( F ) or anti-γH2AX antibodies, respectively. Nuclei were counterstained with DAPI. Percentages of cells with the nucleolar caps were quantified from three experiments. Bars represent mean ± SEM; ns not significant; * P < 0.05; ** P < 0.01; *** P < 0.001.

    Article Snippet: Antibodies used for immunofluorescence (IF) staining: anti-γH2AX (EMD Millipore, #JBW301); Anti-53BP1 (Novusbio, #NB100-304); Fibrillarin(CST, 2639T); anti-Ki-67 (Abcam, #ab15580); anti-C23 (Nucleolin; CST, #14574); anti-UBF (F-9) (Santa Cruz, #sc-13125); anti-BRCA1 (Santa Cruz, #sc-6954); Anti-Rad51 (Santa Cruz, # sc-398587); anti-Myc (Abclonal, #AE070); anti-GFP (Proteintech, #66002-1); Alexa Fluor 594 AffiniPure Goat Anti-Mouse IgG (H + L) (Jackson ImmunoResearch, #115-585-166); Alexa Fluor 488 AffiniPure Goat Anti-Rabbit IgG (H + L) (Jackson ImmunoResearch, #111-545-003); Alexa Fluor 488 AffiniPure Goat Anti-Mouse IgG (H + L) (Jackson ImmunoResearch, #115-545-003); Alexa FluorTM Plus 405 Anti-Rabbit (Invitrogen, # A48254 ); Alexa FluorTM Plus 405 Anti-Mouse (Invitrogen, #A48255).

    Techniques: Immunofluorescence, Labeling

    A The cellular localization of MBLAC2 in HeLa I- Ppo I cells following rDNA DSBs induction. HeLa I- Ppo I cells were transfected with EGFP-MBLAC2 and were treated with Shield-1 and 4-OHT for 4 h. Fixed cells were labeled with anti-53BP1, anti-γH2AX or anti-C23 antibodies. Nuclei were counterstained with DAPI. Enlarged images show the details of the indicated proteins. Quantification of relative signal intensities of EGFP-EHMT2, 53BP1, γH2AX and C23 was performed by ImageJ. The white lines in the enlargements of the representative images indicate the lines for analysis. The edge of the indicated nucleolar caps was labeled with dotted circle. B Analysis of nucleolar transcription activity by EU incorporation assay in MBLAC2-inactivated HeLa I- Ppo I cells following rDNA DSBs induction. Cells transduced with control (shCTR) or two independent MBLAC2-targeted shRNAs were induced for rDNA DSBs for 4 h. EU nucleolar intensity was subsequently determined by EU incorporation assay. At least 200 cells exhibiting well-circumscribed nucleoli were quantitatively assessed across two independent experiments. Quantification of relative EU nucleolar intensity is shown in Tukey boxplots. C Nucleolar EU intensities were analyzed in HeLa I- Ppo I cells treated with the EHMT2 gRNA or MBLAC2 siRNA after I- Ppo I induction. Relative nucleolar EU intensity was quantified from at least two independent experiments. Immunoblot of MBLAC2 and EHMT2 in the HeLa I- Ppo I cells induced with the indicated gRNA or siRNA. D Colony survival of HeLa I- Ppo I cells transfected with CTR siRNA and siRNA targeting MBLAC2 or EHMT2 following I- Ppo I induction, respectively. Cells were induced for rDNA DSBs for 5 min. After washing with PBS twice, cells were allowed to grow for two weeks before harvest and Coomassie blue staining. The relative outgrowth of the colonies between groups were quantified and plotted. The protein expression of MBLAC2 and EHMT2 in HeLa I- Ppo I cells transfected with the indicated siRNAs were examined by immunoblot. E Immunoblot of MBLAC2 and EHMT2 in the HeLa I- Ppo I cells transduced with control gRNA (CTR gRNA) and two EHMT2 gRNAs (EHMT2 KO1 and EHMT2 KO2). F shRNA-mediated MBLAC2 knockdown efficiency was measured by Western blotting. G The EHMT2-MBLAC2 interaction was confirmed by Co-immunoprecipitation (Co-IP). Flag-DYRK1B was used as the positive control. H HeLa I- Ppo I cells transduced with control gRNA (CTR gRNA) and two EHMT2 gRNAs (EHMT2 KO1 and EHMT2 KO2) were treated with cycloheximide for 0, 5, and 10 h. The protein expression of MBLAC2 and EHMT2 in HeLa I- Ppo I cells was examined by immunoblot. I The relative MBLAC2 protein level in HeLa I-PpoI cells treated with cycloheximide as depicted in ( A ) was measured. Data were derived from three independent experiments. J HeLa I-PpoI cells were transduced with control gRNA (CTR gRNA) and two EHMT2 gRNAs (EHMT2 KO1 and EHMT2 KO2). Fold change of MBLAC2 mRNA in I- Ppo I cells treated with cycloheximide was determined by RT-qPCR. Quantification of MBLAC2 mRNA fold change was from three independent experiments. K Proposed working model of EHMT2-MBLAC2 axis in promoting rDNA DSB-induced transcriptional suppression. Bars represent mean ± SEM; ns not significant; * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.

    Journal: Cell Death & Disease

    Article Title: The EHMT2-MBLAC2 axis suppresses ribosomal DNA transcription in response to nucleolar DNA damage

    doi: 10.1038/s41419-026-08616-1

    Figure Lengend Snippet: A The cellular localization of MBLAC2 in HeLa I- Ppo I cells following rDNA DSBs induction. HeLa I- Ppo I cells were transfected with EGFP-MBLAC2 and were treated with Shield-1 and 4-OHT for 4 h. Fixed cells were labeled with anti-53BP1, anti-γH2AX or anti-C23 antibodies. Nuclei were counterstained with DAPI. Enlarged images show the details of the indicated proteins. Quantification of relative signal intensities of EGFP-EHMT2, 53BP1, γH2AX and C23 was performed by ImageJ. The white lines in the enlargements of the representative images indicate the lines for analysis. The edge of the indicated nucleolar caps was labeled with dotted circle. B Analysis of nucleolar transcription activity by EU incorporation assay in MBLAC2-inactivated HeLa I- Ppo I cells following rDNA DSBs induction. Cells transduced with control (shCTR) or two independent MBLAC2-targeted shRNAs were induced for rDNA DSBs for 4 h. EU nucleolar intensity was subsequently determined by EU incorporation assay. At least 200 cells exhibiting well-circumscribed nucleoli were quantitatively assessed across two independent experiments. Quantification of relative EU nucleolar intensity is shown in Tukey boxplots. C Nucleolar EU intensities were analyzed in HeLa I- Ppo I cells treated with the EHMT2 gRNA or MBLAC2 siRNA after I- Ppo I induction. Relative nucleolar EU intensity was quantified from at least two independent experiments. Immunoblot of MBLAC2 and EHMT2 in the HeLa I- Ppo I cells induced with the indicated gRNA or siRNA. D Colony survival of HeLa I- Ppo I cells transfected with CTR siRNA and siRNA targeting MBLAC2 or EHMT2 following I- Ppo I induction, respectively. Cells were induced for rDNA DSBs for 5 min. After washing with PBS twice, cells were allowed to grow for two weeks before harvest and Coomassie blue staining. The relative outgrowth of the colonies between groups were quantified and plotted. The protein expression of MBLAC2 and EHMT2 in HeLa I- Ppo I cells transfected with the indicated siRNAs were examined by immunoblot. E Immunoblot of MBLAC2 and EHMT2 in the HeLa I- Ppo I cells transduced with control gRNA (CTR gRNA) and two EHMT2 gRNAs (EHMT2 KO1 and EHMT2 KO2). F shRNA-mediated MBLAC2 knockdown efficiency was measured by Western blotting. G The EHMT2-MBLAC2 interaction was confirmed by Co-immunoprecipitation (Co-IP). Flag-DYRK1B was used as the positive control. H HeLa I- Ppo I cells transduced with control gRNA (CTR gRNA) and two EHMT2 gRNAs (EHMT2 KO1 and EHMT2 KO2) were treated with cycloheximide for 0, 5, and 10 h. The protein expression of MBLAC2 and EHMT2 in HeLa I- Ppo I cells was examined by immunoblot. I The relative MBLAC2 protein level in HeLa I-PpoI cells treated with cycloheximide as depicted in ( A ) was measured. Data were derived from three independent experiments. J HeLa I-PpoI cells were transduced with control gRNA (CTR gRNA) and two EHMT2 gRNAs (EHMT2 KO1 and EHMT2 KO2). Fold change of MBLAC2 mRNA in I- Ppo I cells treated with cycloheximide was determined by RT-qPCR. Quantification of MBLAC2 mRNA fold change was from three independent experiments. K Proposed working model of EHMT2-MBLAC2 axis in promoting rDNA DSB-induced transcriptional suppression. Bars represent mean ± SEM; ns not significant; * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.

    Article Snippet: Antibodies used for immunofluorescence (IF) staining: anti-γH2AX (EMD Millipore, #JBW301); Anti-53BP1 (Novusbio, #NB100-304); Fibrillarin(CST, 2639T); anti-Ki-67 (Abcam, #ab15580); anti-C23 (Nucleolin; CST, #14574); anti-UBF (F-9) (Santa Cruz, #sc-13125); anti-BRCA1 (Santa Cruz, #sc-6954); Anti-Rad51 (Santa Cruz, # sc-398587); anti-Myc (Abclonal, #AE070); anti-GFP (Proteintech, #66002-1); Alexa Fluor 594 AffiniPure Goat Anti-Mouse IgG (H + L) (Jackson ImmunoResearch, #115-585-166); Alexa Fluor 488 AffiniPure Goat Anti-Rabbit IgG (H + L) (Jackson ImmunoResearch, #111-545-003); Alexa Fluor 488 AffiniPure Goat Anti-Mouse IgG (H + L) (Jackson ImmunoResearch, #115-545-003); Alexa FluorTM Plus 405 Anti-Rabbit (Invitrogen, # A48254 ); Alexa FluorTM Plus 405 Anti-Mouse (Invitrogen, #A48255).

    Techniques: Transfection, Labeling, Activity Assay, Transduction, Control, Western Blot, Staining, Expressing, shRNA, Knockdown, Immunoprecipitation, Co-Immunoprecipitation Assay, Positive Control, Derivative Assay, Quantitative RT-PCR

    Ai , Left, representative immunocytochemistry micrographs of detyrMT (green), actin (red) and nuclei (HOECHST, blue). White arrow indicates detyrMT inside the NI. Right, scatter plot of NI quantification in control, PTL and CytD-treated cardiomyocytes (N=3-5 rats, 44-106 nuclei). Aii , Line-scan schematic of cytoplasmic and nucleoplasmic CaTs in a cardiomyocyte. Aiii , Representative recordings of distinct subcellular regions, as indicated in (ii), baseline quantification in control, PTL and CytD at 1 and 2.5Hz (bottom) (N=3-4 rats, 32-36 cells). Bi , Left, representative immunocytochemistry micrographs of nucleolin (yellow) and nuclei (HOECHST, blue). White arrow indicates NI-nucleoli localization. Right, scatter plots of area, circularity (N=5 rats,162-209 nucleoli) and NI number (N=3 rats, 60-57 nuclei) in control and BMH21-treated cells. Ci , Left, representative immunohistochemistry micrographs α-actinin (red) and nuclei (HOECHST, blue). Right, scatter plot of NI quantification in donor and DCM tissue (N=8 patients, 99-120 cells). Di , Animal model schematic. Representative immunocytochemistry micrographs of nuclei (HOECHST, grey) in Dii and detyrMT (grey) in Diii . Scatter plots of NI quantification ( Dii ) in control, 8-weeks and 16-weeks MI cardiomyocytes (N=3-4 rats, 40-44 cells) and detyrMT area quantification in control and 8-weeks MI cardiomyocytes (N=3 rats, 35-42 cells). Div , Left, mechano-Scanning Ion Conductance Microscopy representative topography and Young’s modulus maps. Right, Young’s modulus quantification in control and 8-weeks MI (N=3 rats, 33-36 cells). Representative immunocytochemistry micrographs of nucleolin (magenta) and nuclei (HOECHST, blue) in Ei and nucleophosmin (magenta), γH2AX-DNA damage (green) and nuclei (HOECHST, blue) in Eii . Scatter plots of circularity (N=3-4 rats, 96-137 nucleoli) and chromocenter Manders Coefficient (M1,M2) (N=3 rats, 43-49 cells) in control and MI cardiomyocytes ( Ei ) and γH2AX foci area ( Eii ) (N=3 rats, 48-63 cells). Eiii , Left, representative heatmap. Right, Brillouin shift absolute difference in control and 8-weeks cardiomyocytes (N=3 rats, 36-37 cells). Statistics: nested t-test ( Bi , Diii-iv ), unpaired t-test Kolmogorov-Smirnov ( Bi , Ci , Ei-iii ), non-parametric Kruskal Wallis with Dunn’s multiple comparison ( Ai , Dii , Ei ).Normality tested with Shapiro-Wilk.Data represent mean±SEM. Scale bar 5µm.

    Journal: bioRxiv

    Article Title: Nucleoli as drivers of nuclear remodelling in cardiomyocytes during Heart Failure

    doi: 10.64898/2026.02.24.707499

    Figure Lengend Snippet: Ai , Left, representative immunocytochemistry micrographs of detyrMT (green), actin (red) and nuclei (HOECHST, blue). White arrow indicates detyrMT inside the NI. Right, scatter plot of NI quantification in control, PTL and CytD-treated cardiomyocytes (N=3-5 rats, 44-106 nuclei). Aii , Line-scan schematic of cytoplasmic and nucleoplasmic CaTs in a cardiomyocyte. Aiii , Representative recordings of distinct subcellular regions, as indicated in (ii), baseline quantification in control, PTL and CytD at 1 and 2.5Hz (bottom) (N=3-4 rats, 32-36 cells). Bi , Left, representative immunocytochemistry micrographs of nucleolin (yellow) and nuclei (HOECHST, blue). White arrow indicates NI-nucleoli localization. Right, scatter plots of area, circularity (N=5 rats,162-209 nucleoli) and NI number (N=3 rats, 60-57 nuclei) in control and BMH21-treated cells. Ci , Left, representative immunohistochemistry micrographs α-actinin (red) and nuclei (HOECHST, blue). Right, scatter plot of NI quantification in donor and DCM tissue (N=8 patients, 99-120 cells). Di , Animal model schematic. Representative immunocytochemistry micrographs of nuclei (HOECHST, grey) in Dii and detyrMT (grey) in Diii . Scatter plots of NI quantification ( Dii ) in control, 8-weeks and 16-weeks MI cardiomyocytes (N=3-4 rats, 40-44 cells) and detyrMT area quantification in control and 8-weeks MI cardiomyocytes (N=3 rats, 35-42 cells). Div , Left, mechano-Scanning Ion Conductance Microscopy representative topography and Young’s modulus maps. Right, Young’s modulus quantification in control and 8-weeks MI (N=3 rats, 33-36 cells). Representative immunocytochemistry micrographs of nucleolin (magenta) and nuclei (HOECHST, blue) in Ei and nucleophosmin (magenta), γH2AX-DNA damage (green) and nuclei (HOECHST, blue) in Eii . Scatter plots of circularity (N=3-4 rats, 96-137 nucleoli) and chromocenter Manders Coefficient (M1,M2) (N=3 rats, 43-49 cells) in control and MI cardiomyocytes ( Ei ) and γH2AX foci area ( Eii ) (N=3 rats, 48-63 cells). Eiii , Left, representative heatmap. Right, Brillouin shift absolute difference in control and 8-weeks cardiomyocytes (N=3 rats, 36-37 cells). Statistics: nested t-test ( Bi , Diii-iv ), unpaired t-test Kolmogorov-Smirnov ( Bi , Ci , Ei-iii ), non-parametric Kruskal Wallis with Dunn’s multiple comparison ( Ai , Dii , Ei ).Normality tested with Shapiro-Wilk.Data represent mean±SEM. Scale bar 5µm.

    Article Snippet: Primary antibodies used: anti-mouse α-actinin (Sigma, MA1-22863), anti-rabbit detyrosinated tubulin (Invitrogen, MA5-44591), anti-rabbit nucleolin (Cell Signaling, #14574), anti-mouse nucleophosmin (Abcam, ab10530), γH2AX (Cell Signaling, #5438).

    Techniques: Immunocytochemistry, Control, Immunohistochemistry, Animal Model, Microscopy, Comparison